menu

CME: COVID-19: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society-led International

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
COVID-19 Resource Center

COVID-19: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society-led International Task Force

close
0.25 credits
15 Minutes
COVID-19: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society-led International Task Force
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    There is little empirical evidence to guide the management of COVID-19. However, with new cases being confirmed daily and the rate still increasing, clinicians taking care of patients with COVID-19 need guidance now. That’s why, with the support of the American Thoracic Society, an international task force of clinicians from academic centers on the frontline of COVID-19 management was convened to develop interim consensus guidance which will be reevaluated as evidence accumulates. This program provides a summary of that guidance to date.

  • Disclosure of Conflicts of Interest

    Faculty Disclosure:
    Dr Wilson has disclosed no relevant financial relationships.

    Accreditor Disclosure:

    • Margaret V. Clark, MSc, RN, RRT - NPS, CMPP, Medical Writer/Interviewer: has disclosed no relevant financial relationships.
    • Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner: has disclosed no relevant financial relationships.
    • Patricia Brignoni, AKH Director of Operations: has disclosed no relevant financial relationships.
    • Steve Eckert, AKH President & CEO, Planner: has disclosed no relevant financial relationships.

    Disclosure Declaration
    It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc., Advancing Knowledge in Healthcare, planners and reviewers have no relevant financial relationships to disclose.

    Disclosure of Unlabeled Use
    This educational activity will include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

  • Target Audience

    This activity is designed for healthcare providers involved in the testing and treatment of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Discuss the interim guidance on management pending empirical evidence of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Accreditation and Credit Designation Statements

    CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

    Nurses
    AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

    This activity is awarded 0.25 Contact Hours.

    Nurse Practitioners
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

    This activity is approved for 0.25 contact hour(s) which includes 0.25 hour(s) of pharmacology. Activity ID # 22095 

    This activity was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support

    Pharmacists
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based CPE activity is approved for 0.25 contact hour(s) (0.025 CEUs). UAN 0077-0000-20-004-H04-P. Initial Release Date: April 9, 2020

    If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com. There is no fee for this activity.

  • Special Acknowledgement

    The ATS would like to acknowledge Boehringer Ingelheim Pharmaceuticals, Inc., for making a charitable donation to support the ATS COVID-19 Crisis Fund, which supports this webinar. No industry funds were applied to the development of this guidance document.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Playlist
Details
Presenters
Related
Comments
  • Overview

    There is little empirical evidence to guide the management of COVID-19. However, with new cases being confirmed daily and the rate still increasing, clinicians taking care of patients with COVID-19 need guidance now. That’s why, with the support of the American Thoracic Society, an international task force of clinicians from academic centers on the frontline of COVID-19 management was convened to develop interim consensus guidance which will be reevaluated as evidence accumulates. This program provides a summary of that guidance to date.

  • Disclosure of Conflicts of Interest

    Faculty Disclosure:
    Dr Wilson has disclosed no relevant financial relationships.

    Accreditor Disclosure:

    • Margaret V. Clark, MSc, RN, RRT - NPS, CMPP, Medical Writer/Interviewer: has disclosed no relevant financial relationships.
    • Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner: has disclosed no relevant financial relationships.
    • Patricia Brignoni, AKH Director of Operations: has disclosed no relevant financial relationships.
    • Steve Eckert, AKH President & CEO, Planner: has disclosed no relevant financial relationships.

    Disclosure Declaration
    It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc., Advancing Knowledge in Healthcare, planners and reviewers have no relevant financial relationships to disclose.

    Disclosure of Unlabeled Use
    This educational activity will include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

  • Target Audience

    This activity is designed for healthcare providers involved in the testing and treatment of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Discuss the interim guidance on management pending empirical evidence of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Accreditation and Credit Designation Statements

    CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

    Nurses
    AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

    This activity is awarded 0.25 Contact Hours.

    Nurse Practitioners
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

    This activity is approved for 0.25 contact hour(s) which includes 0.25 hour(s) of pharmacology. Activity ID # 22095 

    This activity was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support

    Pharmacists
    AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    AKH Inc., Advancing Knowledge in Healthcare approves this knowledge-based CPE activity is approved for 0.25 contact hour(s) (0.025 CEUs). UAN 0077-0000-20-004-H04-P. Initial Release Date: April 9, 2020

    If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com. There is no fee for this activity.

  • Special Acknowledgement

    The ATS would like to acknowledge Boehringer Ingelheim Pharmaceuticals, Inc., for making a charitable donation to support the ATS COVID-19 Crisis Fund, which supports this webinar. No industry funds were applied to the development of this guidance document.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 10/29/20